Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

This study is looking at how well lorlatinib works as a first-line treatment for patients in China with advanced non-small cell lung cancer (NSCLC) whose tumors have a specific genetic change called an ALK-positive mutation. Lorlatinib is a targeted therapy designed specifically for this type of lung cancer. **You may be eligible if...** - You have been diagnosed with stage IIIB/C or stage IV non-small cell lung cancer - Your tumor has tested positive for the ALK mutation (confirmed by an approved test) - You have at least one measurable tumor outside the brain on imaging - You have not previously received ALK-targeted therapy - You are in reasonably good health **You may NOT be eligible if...** - You have already been treated with lorlatinib or another ALK inhibitor - You have uncontrolled brain metastases - You have significant heart, liver, or other organ problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.